Clinical evidence dossier
Metformin
HbA1c
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 11
- Supporting studies available for review
- 11
- Randomized trials
- 8
- Reported effects
- 19
Clinical conclusion
Metformin shows a strong positive evidence signal for improving HbA1c across the studied comparisons.
Observed effects
Observed study estimates; not a pooled treatment effect.
Change from baseline
Absolute change
-1.74 to -0.2 %
Change from baseline
Mean difference
-1.9 to -0.49 %
Between-group effect
Mean difference
0.23 to 0.4 %
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 3
- Magnitude-eligible effects
- 19
Consistency
Authoritative consistency classification
mostly_consistent
- Positive
- 7
- No effect
- 3
- Mixed
- 1
- Negative
- 0
Population and applicability
Structured population data were available for 10 of 11 supporting studies. Diabetes type was heterogeneous: 5 studies with type 2 diabetes, 2 studies with type 1 diabetes. 8 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Young Adult (19–39)
- Middle Aged (40-64)
- Male
- Female
- with T2 Diabetes
- Adults diagnosed with type 2 diabetes
- Individuals seeking dietary interventions for diabetes management
- Adults diagnosed with type 2 diabetes.
- Individuals seeking improved glycemic control with fewer gastrointestinal side effects.
- Participants classified as overweight or obese
- Pregnant women diagnosed with type 1 diabetes.
- Participants who require insulin management during pregnancy.
Limitations
- 3 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.
- 3 supporting studies do not have a displayable topic-matched quantitative effect.
- Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, placebo, unknown_unresolved, usual_care.
- 1 supporting study lacks usable structured population information.
- 4 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.
- 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.